Cellbyte
Backed byFrontline VenturesAbout Cellbyte
Cellbyte is building an AI-native platform to help pharma companies launch new drugs worldwide. The company empowers pharma commercial teams to cut through complexity, analyze previously fragmented data in seconds, and automate high-stakes workflows. It builds AI agents for pharmaceutical drug launches and automates repetitive workflows on a robust data foundation, helping bring life-changing treatments to patients faster. Backed by Y-Combinator, Cellbyte positions itself as an AI-native platform for pharma drug launches.
Open positions
Company at a glance
About the Team
Team Distribution
- Leadership40%
- Engineering40%
- Operations20%
Where the Team Studied
- 1.Technical University of Munich
- 2.Ludwig-Maximilians-Universität München
- 3.Freie Universität Berlin
- 4.Durham University
- 5.RWTH Aachen University
Team Worked At
- Kinapse
- Celonis
- BCG
- Siemens
- appliedAI Initiative GmbH
Funding History
$2.8M
raised
AI drug-launch platform Cellbyte raised a $2.75 million seed round led by Frontline Ventures with participation from Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels.
